Background: Favorable outcomes in treating H pylori infection using “dual therapy (proton pump inhibitor and amoxicillin four times daily)” have attracted widespread attention. However, there are few reports, and the study results lack agreement. This study aimed to compare the eradication rate, safety, and compliance of naïve‐treatment patients with H pylori infection on “dual therapy” with those on “triple plus bismuth (TPB) therapy.”Methods: This is a non‐inferior randomized controlled trial conducted on 760 patients with H pylori infection. The participants were randomly assigned to two eradication groups: dual therapy (esomeprazole 20 mg and amoxicillin 750 mg four times daily) and TPB therapy (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg twice daily) for 14 days. Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed about 8 weeks after eradication to evaluate outcome. Antibiotic resistance and CYP2C19 polymorphism were determined.Results: Compared with TPB therapy, dual therapy had significantly higher eradication rates in intention‐to‐treat (87.1% vs 80.5%, rate difference 6.6%), modified intention‐to‐treat (90.9% vs 85.5%, 5.5%) and per‐protocol (92.4% vs 87.8%, 4.7%) analyses, respectively. Adverse reactions in dual therapy group were significantly lower than TPB therapy group (17.6% vs 25.5%, P = .008), and dual therapy group had better compliance (96.3% vs 92.3%, P = .019). Antibiotic resistance and poor compliance were also associated with treatment failure.Conclusions: Dual therapy (esomeprazole and amoxicillin four times daily) was non‐inferior to, and even superior to TPB therapy as first‐line H pylori eradication.
8 January 2026 in Case Reports in Gastrointestinal Medicine
Background: Myelodysplastic syndromes (MDSs) are clonal hematopoietic disorders often associated with cytogenetic abnormalities, among which trisomy 8 is one of the most common abnormalities. Trisomy 8 is linked to autoimmune manifestations, including Behçet‐like disease, especially with gastrointestinal involvement. Case Presentation: We report a rare and severe case of a 59‐year‐old male with MDS characterized by a complex abnormal karyotype, including trisomy 8, accompanied by multiple ileal perforations and intestinal ulcers resembling Behçet’s disease. Despite surgical intervention and broad‐spectrum antimicrobials, recurrent symptoms persisted. A combination of corticosteroids and thalidomide ultimately led to clinical and hematologic improvement. Methods: Clinical, radiologic, histopathologic, and cytogenetic data were collected. Literature review was conducted to contextualize diagnostic criteria and treatment strategies. Results: The patient showed hematologic and symptomatic improvement following immunosuppressive therapy. Chromosome karyotype analysis revealed chromosomal numerical abnormalities, including trisomy of chromosomes 8, 9, and 15 and the presence of an extra Y chromosome. Gastrointestinal involvement with recurrent perforations was attributed to Behçet‐like intestinal disease. Conclusion: This case underscores the aggressive clinical course and diagnostic challenges of Behçet‐like disease associated with MDS and trisomy 8, highlighting the importance of early recognition and immune‐targeted therapy.